Neurocrine Biosciences (NBIX) Tops Q4 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
February 4, 2020 4:01 PM ESTSAN DIEGO, Feb. 4, 2020 /PRNewswire/ --Â Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2019 and provided full-year 2020 financial expense guidance.
"I am very pleased with the accomplishments of Neurocrine Biosciences this past year, including our quarterly and full-year business results. We anticipate an exciting year... More
